Dain Hård Nevonen

Partner
  • Stockholm
  • Languages:
    Swedish, English

Mentions

Dain Hård Nevonen is ranked as Notable practitioner at IFLR 1000 2019

Dain Hård Nevonen is ranked as ”Really excellent and a rising star” at IFLR1000 2014

Education

  • School of Business, Economics and Law, University of Gothenburg, LL.M., 2006
  • Radboud University, Nijmegen, the Netherlands, 2005

Experience

  • Davis Polk & Wardwell LLP, Foreign Associate, New York, 2011/2012
  • School of Business, Economics and Law, University of Gothenburg, Guest Lecturer Capital Markets Law, 2009/2010

Mandates

Mandate September 10, 2021

Vinge has advised Acrinova in connection with a share issue

Vinge has advised Acrinova, an entrepreneurial real estate company operating in the south of Sweden…

Mandate August 17, 2021

Vinge advises Calliditas Therapeutics in connection with a directed share issue

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…

Mandate June 11, 2021

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Prem…

Mandate June 10, 2021

Vinge has advised SOZAP in connection with its capital raising and listing on Nasdaq First North Growth Market

The company description was published on 3 June 2021 and the trading on Nasdaq First North Premier b…

Mandate June 04, 2021

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq…

Mandate March 30, 2021

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the…

Mandate March 29, 2021

Vinge advises Klövern in connection with the public offer from Corem Property Group

Corem Property Group AB (publ) has announced a public offer to the shareholders of Klövern AB (publ)…

Mandate March 11, 2021

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…

Mandate January 26, 2021

Vinge has advised EQT in connection with the combination with Exeter Property Group

Vinge has advised EQT in connection with the signing of a combination with Exeter Property Group, a…

Mandate December 14, 2020

Vinge is advising Medivir in connection with its rights issue

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir wit…

Mandate October 23, 2020

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed…

Mandate October 16, 2020

Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB

The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EU…

Mandate October 09, 2020

Vinge advises Cell Impact AB (publ) in connection with a directed share issue

Vinge has advised Cell Impact AB (publ) in connection with a directed share issue, whereby Cell Impa…

Mandate August 13, 2020

Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…

Mandate July 13, 2020

Vinge advises Hansa Biopharma in connection with a directed share issue

The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the ann…

Mandate June 11, 2020

Vinge advises Medicover in connection with a directed share issue 

The board of directors of Medicover has, on the basis of an authorisation granted from the annual ge…

Mandate June 10, 2020

Vinge advises Calliditas

Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasd…

Mandate June 04, 2020

Vinge advises Nanoform in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden

Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listi…

Mandate May 11, 2020

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…

Mandate May 06, 2020

Vinge has advised Equinor ASA in connection with a sale of shares in Lundin Energy

Vinge has advised Equinor ASA in connection with a sale of shares in Lundin Energy AB (publ) through…

Mandate April 01, 2020

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Gro…

Mandate March 05, 2020

Vinge advises Cinclus Pharma in connection with a capital raising

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital…

Mandate January 10, 2020

Vinge has advised Industrifonden and Investinor in connection with a sale of shares in Calliditas

Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately…

Mandate December 13, 2019

Vinge advises IRLAB Therapeutics in connection with share issues

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a r…

Mandate December 10, 2019

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed…

Mandate September 24, 2019

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockh…

Mandate July 12, 2019

Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment

The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleu…

Mandate July 04, 2019

Vinge advises Calliditas in connection with a directed share issue

The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directe…

Mandate June 28, 2019

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…

Mandate May 22, 2019

Vinge assists Nuevolution in connection with Amgen’s cash offer

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the sh…

Mandate January 25, 2019

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…

Mandate December 10, 2018

Vinge advises Xspray Pharma in connection with a directed share issue

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, wh…

Mandate December 06, 2018

Vinge advises Biotage in connection with its acquisition of PhyNexus

Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acqu…

Mandate November 21, 2018

Vinge advised Equinor in connection with its investment in Medfield Diagnostics

Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfi…

Mandate November 15, 2018

Vinge advises Hansa Medical in connection with a directed share issue

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hans…

Mandate October 09, 2018

Vinge advises Klövern on its offer for Agora

Klövern AB (publ) has, through its indirectly wholly-owned subsidiary Dagon Sverige AB, made a publi…

Mandate August 17, 2018

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total v…

Mandate July 03, 2018

Vinge has advised Autoliv and Veoneer

Vinge has advised Autoliv, Inc. (“Autoliv”) and Veoneer, Inc. (“Veoneer”) in connection with the spi…

Mandate June 29, 2018

Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the l…

Mandate June 25, 2018

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premi…

Mandate June 20, 2018

Vinge advises ABG, SEB and Swedbank in connection with a directed share issue in Hemfosa

Vinge advises ABG Sundal Collier, Skandinaviska Enskilda Banken and Swedbank who are acting as Joint…

Mandate May 25, 2018

Vinge advises Nuevolution in connection with a directed share issue

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevol…

Mandate May 24, 2018

Vinge advises IRLAB Therapeutics in connection with a directed share issue

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the…

Mandate March 23, 2018

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…

Mandate January 31, 2018

Vinge advises Xspray Pharma in connection with a directed share issue

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraor…

Mandate December 12, 2017

Vinge advises Lyko Group in connection with its listing on Nasdaq First North Premier

Vinge has advised Lyko Group AB (publ) (“Lyko”) in connection with its listing on Nasdaq First North…

Mandate November 30, 2017

Vinge advises Hansa Medical in connection with directed share issue

The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, sub…

Mandate June 26, 2017

Vinge assisted EQT V Limited in connection with the sale of shares in AcadeMedia AB (publ)

Vinge assisted EQT V Limited (”EQT”) in connection with the sale of shares in AcadeMedia AB (publ) (…

Mandate June 07, 2017

Vinge advises DGC in connection with EQT’s acquisition of shares in DGC and subsequent mandatory offer

Vinge advises DGC One AB (publ) (“DGC”) in connection with EQT’s acquisition of 85.2 percent of the…

Mandate May 23, 2017

Vinge advises Medicover in relation to its listing on Nasdaq Staockholm

Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”),…

Mandate April 27, 2017

Vinge advises Advania on its offer for Caperio Holding

Advania has, through Advania Holding AB, made a recommended cash offer to the shareholders of Caperi…

Mandate October 24, 2016

Vinge advises Hansa Medical in connection with directed share issue

The board of directors of Hansa Medical proposes a capital raising through a directed share issue, w…

News

Update regarding the implications of Covid-19 for upcoming AGMs
News April 03, 2020

Update regarding the implications of Covid-19 for upcoming AGMs

The outbreak of the coronavirus disease has had a significant impact on people and businesses. The s…